نتایج جستجو برای: شرکت novartis
تعداد نتایج: 53699 فیلتر نتایج به سال:
The impact of storage conditions on compound stability and compound solubility has been debated intensely over the past 5 years. At Novartis, the authors decided to opt for a storage concept that can be considered controversial because they are using a DMSO/water (90/10) mixture as standard solvent. To assess the effect of water in DMSO stocks on compound stability, the authors monitored the pu...
Grant Support: J.D.G is supported by NIH grant CA66996, and a Specialized Center of Research Award from the Leukemia and Lymphoma Society. J.D.G. is also supported by NIH grants CA36167 and DK50654. P.W.M., J.M., and D.F. are employees of Novartis Pharma AG, Basel, Switzerland. J.D.G. has a financial interest with Novartis Pharma AG. Blood First Edition Paper, prepublished online October 26, 20...
BACKGROUND Glivec (imatinib mesylate), produced by the pharmaceutical company Novartis, is prescribed in the case of chronic myeloid leukemia, one of the most common blood cancers in eastern countries. After more than a decade of legal battles surrounding its patentability, the Supreme Court of India gave its final decision on April 1st of 2013, rejecting the appeal of the Swiss giant drug manu...
Disclosure: Prof Trautinger has acted as consultant/advisor to AbbVie, Angelini, BMS, Eli Lilly, Galderma, Leo, MSD, Novartis, Roche, and Sanofi; received speaker’s honoraria from BMS, Galderma, Hollister, Leo, MSD, Novartis, and Roche; and received research grants from AbbVie, Angelini, and Roche. Prof Passeron has been an advisor/consultant for AbbVie, Galderma, ISIS Pharma, Janssen, La Roche...
The PI3K-AKT-mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may therefore be effective as anticancer agents. Early clinical studies with PI3K inhibitors have demonstrated preliminary antitumor activity and acceptable...
Acknowledgment: This Editors’ Consensus is supported by an educational grant from Colgate-Palmolive, Inc., New York, New York, and is based on a meeting of the authors held in Boston, Massachusetts, on January 9, 2009. Disclosure: Dr. Friedewald has received honoraria for speaking from Novartis, East Hanover, New Jersey. Dr. Kornman is a full-time employee and shareholder of Interleukin Genetic...
ACKNOWLEDGMENT This Editors' Consensus is supported by an educational grant from Colgate-Palmolive, Inc., New York, New York, and is based on a meeting of the authors held in Boston, Massachusetts, on January 9, 2009. DISCLOSURE Dr. Friedewald has received honoraria for speaking from Novartis, East Hanover, New Jersey. Dr. Kornman is a full-time employee and shareholder of Interleukin Genetic...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید